Skip Navigation

European Heart Journal 2001 22(2):153-164; doi:10.1053/euhj.2000.2175
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Khand, A.U
Right arrow Articles by Cleland, J.G.F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khand, A.U
Right arrow Articles by Cleland, J.G.F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges

A.U Khanda, I Gemmellb, A.C Rankina and J.G.F Clelandc,f1

a Department of Cardiology, Glasgow Royal Infirmary
b Social and Public Health Sciences Unit, University of Glasgow
c Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston-upon-Hull, U. K.

revised March 21, 2000; accepted March 21, 2000

Abstract

Aims To describe the sequence of clinically apparent events causing readmission and antedating death, subsequent to a first-time hospital admission for heart failure, in order to give insights into the natural history and mechanisms of progression of heart failure.

Methods A national database of linked hospital discharge and mortality data for Scotland (population 5·1 million) was used. Patients with a first-time admission to hospital with heart failure in 1992 (index population) were identified and, using a record linkage system, hospital readmissions and their cause according to the hospital physician and deaths were recorded over the subsequent 3 years. A flowchart showing the sequence of events leading to death or recurrent admission was constructed.

Results 12640 patients had first-time admissions with heart failure in 1992; their mean age was 74 years and 46·2% were men. A cohort of 2922 (23%) patients died on their first admission. Among the remaining 9718 patients there were 22747 readmissions and 4877 deaths over the subsequent 3 years; only 15% had neither event reported. Nine per cent of patients died without any readmission and a further 6% without a further readmission for cardiovascular reasons. A cohort of 5992 (61% of patients at risk) had at least one cardiovascular readmission and half of these had occurred within 6 months. Heart failure without a report of any cardiovascular precipitating event was responsible for 37% (2188 patients) of first cardiovascular readmissions and of these patients approximately 12% had evidence of renal failure or acute respiratory infection as possible triggers for readmission. Acute ischaemic events including myocardial infarction (19%), myocardial infarction alone (8%) and atrial fibrillation (11%) were associated with a substantial number of first readmissions. First readmission precipitated by acute myocardial infarction was associated with a particularly poor prognosis (40% inpatient mortality).

Conclusions Recurrent ischaemic events and atrial fibrillation may be the predominant mechanisms leading to exacerbation of and progression of heart failure and death. A substantial proportion of readmissions appear related to heart failure alone. Whether this reflects progressive ventricular remodelling leading to worsening heart failure or other unidentified mechanisms cannot be discerned from this data.

Key Words: Heart failure, atrial fibrillation, left ventricular remodelling, ischaemic heart disease, epidemiology.

f1 Correspondence: Professor John G.F. Cleland, MD, FRCP, FACC, FESC, Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston-upon-Hull, HU16 5JQ, U.K.

References

  1. Mcmurray J, Mcdonagh T, Morrison CE, Dargie HJ. Trends in hospitalisation for heart failure in Scotland 1980–1990. Eur Heart J. 1993;14:1158–1162[Abstract/Free Full Text]
  2. Haldemand GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137:352–360[CrossRef][ISI][Medline]
  3. Reitsma JB, Dalstra JAA, Bonsel GJ. Cardiovascular disease in the Netherlands, 1975 to 1995: decline in mortality, but increasing numbers of patients with chronic conditions. Heart. 1999;82:52–56[Abstract/Free Full Text]
  4. Swedberg K, Idanpaan Heikkila U, Remes J. Effects of enalapril on mortality in severe congestive heart failure. Results of the Coperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Eng J Med. 1987;316:1429–1435[Abstract]
  5. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New Eng J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  6. Lancet. 1999;353:9–13[CrossRef][ISI][Medline]
  7. Ball SG, Hall AS, Mackintosh AF. Effect of ramipril and morbidity of surviviors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828[ISI][Medline]
  8. Cleland JGF, Gemmel I, Khand AU, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Failure. 1999;1:229–241[CrossRef][ISI][Medline]
  9. Teerlink JR, Pfeffer JM, Pfeffer MA. Effect of left ventricular sphericity on the evolution of ventricular dysfunction in rats with diffuse isoproteronol-induced myocardial necrosis. J Cardiac Failure. 1998;4:45–56[Medline]
  10. Torp-Pederson LKC, Kober L, Carlsen J. Angio-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. Am Heart J. 1996;132:235–243[ISI][Medline]
  11. St. John Sutton M, Pfeffer MA, Moye L. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997;96:3294–3299[Abstract/Free Full Text]
  12. Cohn JN, Johnson GR, Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Eng J Med. 1991;325:303–310[Abstract]
  13. Yusuf S, Pepine CJ, Garces C. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173–1178[CrossRef][ISI][Medline]
  14. Rutherford JD, Pfeffer MA, Moye LA. Effects of captopril on ischaemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial SAVE Investigators. Circulation. 1994;90:1731–1738[Abstract/Free Full Text]
  15. Lonn EM, Yusuf S, Montague TJ. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056–2069[Free Full Text]
  16. Cleland JGF, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J. 1997;18:41–51[ISI][Medline]
  17. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Internal Medicine. 1988;148:2013–2016
  18. Krumholz HM, Parent EM, Tu N. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990;38:1290–1295[ISI][Medline]
  19. Cleland JGF, Poole-Wilson PA, Packer M. Critical event pathways for progression of heart failure and mortality: Insights from the ATLAS study. [Abstr]. J Am Coll Cardiol. 1999;33:1228–1228
  20. Anonymous. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Eng J Med. 1991;325:293–302[Abstract]
  21. Remme WJ. Prevention of worsening heart failure: future focus. Eur Heart J. 1998;19:47–53
  22. Patten RD, Udelson JE, Konstam MA. Ventricular remodeling and its prevention in the treatment of heart failure. Curr Opin Cardiol. 1998;13:162–167[ISI][Medline]
  23. Lechat P. Prevention of heart failure progression: current approaches. Eur Heart J. 1998;19:B12–18
  24. Cowie MR, Wood DA, Coats AJS. Incidence and aetiology of heart failure, A population-based study. Eur Heart J. 1999;20:421–428[Abstract/Free Full Text]
  25. Kendrick S, Clarke J. The Scottish Record Linkage System. Health Bull. 1993;51:72–79
  26. Harley K, Jones C. Quality of Scottish Morbidity Record (SMR) Data. Health Bull. 1996;54:410–417
  27. Anonymous. The West of Scotland Coronary Prevention Group: Computerised record linkage compared with traditional patients follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiology. 1995;48:1441–1452[CrossRef][ISI][Medline]
  28. Opasich C, Febo O, Riccardi PG. Concomitant factors of decompensation in chronic heart failure. American Journal of Cardiology. 1996;78:354–357[CrossRef][ISI][Medline]
  29. Krumholz HM, Parent EM, Tu N. Readmission after hospitalization for congestive heart failure among medicare beneficiaries. Arch Intern Med. 1997;157:99–104[Abstract]
  30. Gooding J, Hette AM. Hospital readmissions among the elderly. J Am Geriatr Soc. 1990;33:595–601
  31. Feenstra J, Grobbee DE, Jonkman FAM, Hoes AW, Stricker BHC. Prevention of relapse in patients with congestive heart failure: the role of precipitating factors. Heart. 1998;80:432–436[Abstract/Free Full Text]
  32. Registrar General, Annual Report of the Registrar General For Scotland, 1992, The Scottish Office, Edinburgh, Scotland
  33. Van Den Berg MP, Tuinenberg AE, Crijns HJGM. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 1997;77:309–313[Abstract/Free Full Text]
  34. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J. 1998;19:696–710[Free Full Text]
  35. Khand AU, Rankin AC, Kaye G, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614–632[Abstract/Free Full Text]
  36. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22:6A–13A[Medline]
  37. Cowie MR, Mosterd A, Wood DA. The epidemiology of heart failure. Eur Heart J. 1997;18:208–215[Free Full Text]
  38. Kohli HS, Knil-Jones RP. How accurate are SMR 1 (Scottish Morbidity Record 1). Data. Health Bull. 1992;50:14–23
  39. Patel AR, Gray G, Lang GD, Baillie FGH, Fleming L, Wilson GM. Errors in diagnostic returns. Health Bull. 1976;34:215–220
  40. Murdoch DR, Love MP, Robb SD. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979–1992. Eur Heart J. 1998;19:1829–1835[Abstract/Free Full Text]
  41. Lauer MS, Blackstone EH, Young J, Topol EJ. Cause of Death in Clinical Research. J Am Coll Cardiol. 1999;34:618–620[Free Full Text]
  42. Narang R, Cleland JGF, Erhardt L. Mode of death in chronic heart failure: a request for more accurate classification. Eur Heart J. 1996;17:1390–1403[Abstract/Free Full Text]
  43. Cleland JGF, Massie BM, Packer M. Sudden Death in Heart Failure: vascular or electrical? Eur J Heart Fail. 1999;1:41–45[CrossRef][ISI][Medline]
  44. Uretsky B, Armstrong PW, Cleland JGF. Ischaemia as a 'trigger' for sudden death in patients with cardiomyopathy and heart failure secondary to coronary artery disease: results from the ATLAS trial [Abstr]. Circulation. 1998;199:
  45. Morooka S, Hayashi T, Takayanagi K, Inoue T, Sakai Y, Takabatake Y. Heart Failure progression due to secondary organ dysfunction in acute heart failure. Japan Heart J. 1995;36:29–36
  46. Okaishi K, Morimoto S, Fukuo K. Reduction of Risk of Pneumonia Associated with use of Angiotensin I Converting Enzyme Inhibitors in elderly Inpatients. Am J Hypertension. 1999;99:778–783
  47. Wikstrom G, Malmberg K, Ryden L. Improved knowledge of antidiabetic treatment—a necessity for the modern cardiologist. Eur Heart J. 1999;20:403–405[ISI][Medline]
  48. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80:437–441[Abstract/Free Full Text]
  49. Vinson JM, Rich MW, Sperry JC. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990;38:1290–1295[ISI][Medline]
  50. Pedersen OD, Bagger H, Torp-Pederson LKC. Trandolapril reduces incidence of atrial fibrillation following acute myocardial infarction. Circulation. 1999;100:376–380[Abstract/Free Full Text]
  51. Anonymous. Effects of carvedilol, a vasodilator beta-blocker, in patients with congestive heart failure due to ischaemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation. 1995;92:212–218[Abstract/Free Full Text]
  52. Anonymous. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. First international study of Infarct survival collaborative group. Lancet. 1986;ii:57–66
  53. Pitt B, Zannad F, Remme WJ. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med. 1999;341:709–717[Abstract/Free Full Text]
  54. Pedersen OD. Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function: Atrial Fibrillation in the DIAMOND study [Abstract]. Circulation. 1998;98:I-632
  55. Cappuci A, Aschieri GQ, Villani F, Passerini F, Groppi A. Oral amiodarone increases efficacy of DC cardioversion in patients with chronic atrial fibrillation and organic heart disease. J Am Coll Cardiol. 1997;29:443A
  56. Chapman MJ, Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DN. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Medicine. 1993;19:48–52[CrossRef][ISI][Medline]
  57. Deedwania PC, Singh BN, Ellenbogen KA, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation. 1998;98:2574–2579[Abstract/Free Full Text]
  58. Eur J Heart Fail. 1999;1:95–99[CrossRef][ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
L. Padeletti, P. Pieragnoli, V. Jentzen, and A. Schuchert
The comorbidity of atrial fibrillation and heart failure: a challenge for electrical therapies
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I81 - I86.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Bont, E. Hak, A. W. Hoes, M. Schipper, F. G. Schellevis, and T. J. M. Verheij
A prediction rule for elderly primary-care patients with lower respiratory tract infections
Eur. Respir. J., May 1, 2007; 29(5): 969 - 975.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. de Silva, N. P. Nikitin, K. K.A. Witte, A. S. Rigby, K. Goode, S. Bhandari, A. L. Clark, and J. G.F. Cleland
Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis
Eur. Heart J., March 1, 2006; 27(5): 569 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. J. Calvert, N. Freemantle, G. Yao, J. G.F. Cleland, L. Billingham, J.-C. Daubert, S. Bryan, and on behalf of the CARE-HF Investigators
Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial
Eur. Heart J., December 2, 2005; 26(24): 2681 - 2688.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
G. A. Wellenius, T. F. Bateson, M. A. Mittleman, and J. Schwartz
Particulate Air Pollution and the Rate of Hospitalization for Congestive Heart Failure among Medicare Beneficiaries in Pittsburgh, Pennsylvania
Am. J. Epidemiol., June 1, 2005; 161(11): 1030 - 1036.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. G.F. Cleland
Patients with treatable malignant diseases -- including heart failure -- are entitled to specialist care
Can. Med. Assoc. J., January 18, 2005; 172(2): 207 - 209.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. D. Sackner-Bernstein and H. A. Skopicki
Racing away from bias
J. Am. Coll. Cardiol., March 3, 2004; 43(5): 785 - 786.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Martinez-Selles, J. A.G. Robles, L. Prieto, M. D. Munoa, E. Frades, O. Diaz-Castro, and J. Almendral
Systolic dysfunction is a predictor of long term mortality in men but not in women with heart failure
Eur. Heart J., November 2, 2003; 24(22): 2046 - 2053.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. B. Braunstein, G. F. Anderson, G. Gerstenblith, W. Weller, M. Niefeld, R. Herbert, and A. W. Wu
Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure
J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1226 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. D.R. Thackray, K. K.A. Witte, N. P. Nikitin, A. L. Clark, G. C. Kaye, and J. G.F. Cleland
The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population
Eur. Heart J., June 2, 2003; 24(12): 1143 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M L Bouvy, E R Heerdink, H G M Leufkens, and A W Hoes
Predicting mortality in patients with heart failure: a pragmatic approach
Heart, June 1, 2003; 89(6): 605 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J.G.F Cleland, K Swedberg, F Follath, M Komajda, A Cohen-Solal, J.C Aguilar, R Dietz, A Gavazzi, R Hobbs, J Korewicki, et al.
The EuroHeart Failure survey programme--a survey on the quality of care among patients with heart failure in Europe: Part 1: patient characteristics and diagnosis
Eur. Heart J., March 1, 2003; 24(5): 442 - 463.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
D. A. M. J. Theuns, J. C. J. Res, and L. J. Jordaens
Home monitoring in ICD therapy: future perspectives
Europace, January 1, 2003; 5(2): 139 - 142.
[Abstract] [PDF]

Home page
 EuropaceHome page
L. Padeletti, N. Musilli, M. C. Porciani, A. Colella, L. Di Biase, G. Ricciardi, P. Pieragnoli, A. Michelucci, and G. Gensini
Atrial fibrillation and cardiac resynchronization therapy: the MASCOT study
Europace, January 1, 2003; 5(s1): S49 - S54.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J G F Cleland
Contemporary management of heart failure in clinical practice
Heart, October 1, 2002; 88(90002): ii5 - 8.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
S Orn and K Dickstein
How do heart failure patients die?
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D59 - D65.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Khand, A.U
Right arrow Articles by Cleland, J.G.F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khand, A.U
Right arrow Articles by Cleland, J.G.F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?